Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Free Cash Flow came in at $46.5 million in Q2 2026, up 66.07% YoY from $28.0 million in Q2 2025, and down 7.01% on a QoQ basis from $50.0 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Free Cash Flow data on file, last reported at $46.5 million in Q2 2026.
- Quarterly Free Cash Flow rose 66.07% year-over-year to $46.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $180.6 million (up 172.03% YoY) and the FY2025 annual result came in at $136.4 million, up 755.06% from the prior year.
- Free Cash Flow fell to $46.5 million in Q2 2026, from $50.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $62.1 million in Q3 2022 to a low of -$34.1 million in Q1 2022.
- A 5-year average of $15.3 million and a median of $11.0 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow sank 113.22% — and 2025, when it surged 3799.04%.
- Tracing KNSA's Free Cash Flow over 5 years: stood at -$11.8 million in 2022, then surged by 148.4% to $5.7 million in 2023, then soared by 183.48% to $16.2 million in 2024, then surged by 210.81% to $50.5 million in 2025, then declined by 7.85% to $46.5 million in 2026.
- The last three Free Cash Flow figures came in at $46.5 million (Q2 2026), $50.0 million (Q1 2026), and $50.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.08 Bn | 5.56 Bn | 220.03 Mn | 46.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.53 Mn |
| Jun 30, 2026 | 46.53 Mn |
| Mar 31, 2026 | 50.04 Mn |
| Mar 31, 2026 | 50.04 Mn |
| Dec 31, 2025 | 50.49 Mn |
| Dec 31, 2025 | 50.49 Mn |
| Sep 30, 2025 | 33.53 Mn |
| Sep 30, 2025 | 33.53 Mn |
| Jun 30, 2025 | 28.02 Mn |
| Jun 30, 2025 | 28.02 Mn |
| Mar 31, 2025 | 24.37 Mn |
| Mar 31, 2025 | 24.37 Mn |
| Dec 31, 2024 | 16.25 Mn |
| Dec 31, 2024 | 16.25 Mn |
| Sep 30, 2024 | -2.25 Mn |
| Sep 30, 2024 | -2.25 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 625,000.00 |
| Mar 31, 2024 | 625,000.00 |